Details of the Drug Reposition

General Information of This Drug (ID: DMPNUYZ)

Drug Name
Autologous VEGF-and angiopoietin-1-expressing endothelial and smooth muscle cell therapy   DMPNUYZ
Synonyms
MultiGeneAngio; Autologous VEGF-and angiopoietin-1-expressing endothelial and smooth muscle cell therapy (cardiovascular disease); VEGF-114 based therapy (cardiovascular disease), Compugen/MGVS; VEGF-114 based therapy (cardiovascular disease), Compugen/MultiGene Vascular Systems; Autologous VEGF-and angiopoietin-1-expressing endothelial and smooth muscle cell therapy (cardiovascular disease), Compugen/MGVS; Autologous VEGF-and angiopoietin-1-expressing endothelial and smooth muscle cell therapy (cardiovascular disease), Compugen/MultiGene Vascular Systems

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Cardiovascular disease DIS2IQDX BA00-BE2Z Phase 1/2 [1]
Peripheral arterial disease DIS78WFB BD4Z Phase 1/2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00390767) Safety Study of MultiGeneAngio in Patients With Peripheral Arterial Disease (PAD). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)